Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.60
- Piotroski Score 5.00
- Grade Buy
- Symbol (ASRT)
- Company Assertio Holdings, Inc.
- Price $0.94
- Changes Percentage (-3.09%)
- Change -$0.03
- Day Low $0.93
- Day High $0.99
- Year High $1.80
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $2.88
- High Stock Price Target $3.00
- Low Stock Price Target $2.75
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.65
- Trailing P/E Ratio -0.21
- Forward P/E Ratio -0.21
- P/E Growth -0.21
- Net Income $-331,942,000
Income Statement
Quarterly
Annual
Latest News of ASRT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Assertio Holdings Inc (ASRT) Q2 2024 Earnings Call Highlights: Navigating Sales Challenges and ...
2024 guidance for Assertio includes net product sales of $110M to $125M and adjusted EBITDA of $20M to $30M. CEO Brendan O'Grady is optimistic about the company's value creation potential, growth pros...
By Yahoo! Finance | 1 month ago -
Assertio Holdings (NASDAQ:ASRT) adds US$14m to market cap in the past 7 days, though investors from five years ago are still down 89%
Assertio Holdings, Inc. (NASDAQ:ASRT) stock price rose 47% in the last quarter, but has declined 89% over 5 years. Lack of profitability and declining revenues raise concerns, indicating a need for su...
By Yahoo! Finance | 4 months ago
